entertainment -WSS

entertainment

author：Wikipedia 2025-10-02 22:24:26 - browse：15662

Closeup of a human brain affected by Alzheimer's disease, on display at the Museum of Neuroanatomy at the University at Buffalo in Buffalo, N.Y. — A brain affected by Alzheimer's disease, at the Museum of Neuroanatomy at the University at Buffalo. David Duprey/AP

Investigators on Wednesday released the first detailed case report about a patient who died after receiving lecanemab, providing a new glimpse into safety concerns surrounding the closely watched experimental Alzheimer’s drug.

An unpublished version of the report was previously written about by Science in November, one of three deaths from the lecanemab trials revealed by Science and STAT. But the published version, in the New England Journal of Medicine, will allow doctors to evaluate the case as they consider whether and how to use a treatment that could be approved by the FDA as soon as this week.

This “will have greater impact on clinicians because it is peer-reviewed and published in the New England Journal,” said Lon Schneider, an Alzheimer’s expert at University of Southern California, who was not affiliated with the work.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Surge of respiratory disease in China has likely explanation

focus

WSS

Medicaid rebukes states for mistakenly disenrolling children

Weight loss drug costs may need more research, senator suggests

Amazon on where the company's health care bets are headed next

NIH nominee Bertagnolli will get October confirmation hearing

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

The (many) problems with a new study criticizing cancer screening

leisure time

entertainment

focus

State Dept. review finds Biden bears some blame for Afghanistan failures

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Novavax promises a turnaround & Lilly roils the obesity market

Childhood cancer progress stalls for Black, Hispanic kids: Report

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

In key trial, Verve's treatment lowers cholesterol levels in patients

At least 13 dead in Texas as scorching temps continue

Weight loss drug costs may need more research, senator suggests

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

A rare thyroid diagnosis led to unexpected, all

focus

In key trial, Verve's treatment lowers cholesterol levels in patients

What drug price negotiations mean for Medicare Part D

Gain of function research would be limited under House proposal

Does good food count as health care? Study aims to find out

NYU radiologists take on the challenge of expensive MRI machines

Stem cell treatment guidelines are released by FDA

focus

hotspot

hotspot

hotspot